Akebia Therapeutics, Inc. (AKBA)

Market Cap	399.27M
Revenue (ttm)	169.88M
Net Income (ttm)	-45.99M
Shares Out	218.18M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,616,573
Open	1.770
Previous Close	1.790
Day's Range	1.750 - 1.870
52-Week Range	0.800 - 2.480
Beta	0.70
Analysts	Strong Buy
Price Target	7.50 (+309.84%)
Earnings Date	Nov 7, 2024

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult pa...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Mar 20, 2014
• Employees: 167
• Stock Exchange: NASDAQ
• Ticker Symbol: AKBA
• Website: https://www.akebia.com

Financial Performance

In 2023, Akebia Therapeutics's revenue was $194.62 million, a decrease of -33.46% compared to the previous year's $292.48 million. Losses were -$51.93 million, -44.89% less than in 2022.

Analyst Forecast

According to one analyst, the rating for AKBA stock is "Strong Buy" and the 12-month stock price forecast is $7.5.

Price Target

$7.5

(309.84% upside)

Analyst Consensus: Strong Buy